Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients
Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…The prevalence of gastrointestinal disorders and non-motor symptoms in a cohort of patients with Parkinson’s disease
Objective: The aim of this investigation was to estimate the prevalence of gastrointestinal disorders (GID) and non-motor symptoms (NMS) in a cohort of a cohort…Irritable bowel syndrome is more prevalent than functional constipation in Parkinson’s disease: Clinical spectrum and changes in gut microbiota
Objective: To assess distal functional gastrointestinal (GI) symptoms and their connection to fecal microbiota (FM) in Parkinson (PD) patients. Background: The majority of PD patients…Are inflammatory bowel disease and/or treatment with aminosalicylates protective factors against Parkinson’s disease?
Objective: To analyze the association between aminosalicylate-treated inflammatory bowel disease (IBD-A) and Parkinson´s disease (PD) at population level. Background: According to the dual-hit hypothesis, the…Differences of gut bacterial community relate to pathology progress in Parkinson’s disease
Objective: The aim of this study is to examine whether intestinal microbiota correlate with progression of clinical severity and serum inflammation marker. Background: Constipation is…
- « Previous Page
- 1
- …
- 8
- 9
- 10